ERBB2 and neoplasm: T-DXd has shown significant anti-tumor activity in patients with heavily pre-treated HER2-positive metastatic breast cancer [10], thus leading to an accelerated Food and Drug Administration (FDA, Silver Spring, MD, USA) approval in 2019 [11].